|
ES2434840T3
(es)
|
1995-07-27 |
2013-12-17 |
Genentech, Inc. |
Formulación de proteína liofilizada isotónica estable
|
|
US6624142B2
(en)
|
1997-12-30 |
2003-09-23 |
Enzon, Inc. |
Trimethyl lock based tetrapartate prodrugs
|
|
WO2000018422A1
(fr)
|
1998-09-28 |
2000-04-06 |
Santen Pharmaceutical Co., Ltd. |
Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
|
|
PE20010212A1
(es)
|
1999-06-01 |
2001-02-22 |
Neuralab Ltd |
Composiciones del peptido a-beta y procesos para producir las mismas
|
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
|
WO2004047871A2
(en)
|
2002-11-26 |
2004-06-10 |
Nobex Corporation |
Modified naturetic compounds, conjugates, and uses thereof
|
|
US7332164B2
(en)
|
2003-03-21 |
2008-02-19 |
Enzon Pharmaceuticals, Inc. |
Heterobifunctional polymeric bioconjugates
|
|
PL1620118T3
(pl)
|
2003-04-08 |
2014-11-28 |
Yeda Res & Dev |
Leki odwracalnie pegylowane
|
|
CA2763817C
(en)
|
2003-04-08 |
2014-05-27 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
CA2940803A1
(en)
|
2004-03-23 |
2005-10-27 |
Ascendis Pharma Gmbh |
Prodrug linker
|
|
GB2427360A
(en)
|
2005-06-22 |
2006-12-27 |
Complex Biosystems Gmbh |
Aliphatic prodrug linker
|
|
CU23556A1
(es)
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
CN101541347B
(zh)
*
|
2006-08-02 |
2012-10-31 |
内布拉斯加大学评议会 |
药物载体、其合成及其使用方法
|
|
US8283318B2
(en)
*
|
2006-09-08 |
2012-10-09 |
Mayo Foundation For Medical Education And Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
|
MX2009002859A
(es)
|
2006-09-15 |
2009-03-30 |
Enzon Pharmaceuticals Inc |
Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
|
|
WO2008067127A2
(en)
|
2006-11-09 |
2008-06-05 |
Alcon Research, Ltd. |
Water insoluble polymer matrix for drug delivery
|
|
CA2681567C
(en)
|
2007-03-22 |
2016-07-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
|
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
|
SI2173890T1
(sl)
|
2007-06-21 |
2011-06-30 |
Univ Muenchen Tech |
Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
|
|
JP2010533202A
(ja)
|
2007-07-11 |
2010-10-21 |
エンゾン ファーマシューティカルズ，インコーポレーテッド |
多置換芳香族部分を含むポリマー性薬剤送達システム
|
|
EP2217620A2
(en)
*
|
2007-11-21 |
2010-08-18 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
|
BRPI0821591A2
(pt)
|
2007-12-21 |
2016-05-03 |
Inspiration Biopharmaceuticals Inc |
composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
|
|
AU2009209565B2
(en)
|
2008-02-01 |
2013-09-19 |
Ascendis Pharma As |
Prodrug comprising a self-cleavable linker
|
|
WO2009143412A2
(en)
|
2008-05-23 |
2009-11-26 |
Enzon Pharmaceuticals, Inc. |
Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
|
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
|
EP2334335A1
(en)
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of cd-np peptides
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
PT2432489T
(pt)
*
|
2009-05-20 |
2016-12-07 |
Biomarin Pharm Inc |
Variantes do péptido natriurético de tipo c
|
|
WO2011012722A1
(en)
|
2009-07-31 |
2011-02-03 |
Ascendis Pharma As |
Prodrugs containing an aromatic amine connected by an amido bond to a linker
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
MX337432B
(es)
|
2009-12-15 |
2016-03-04 |
Ascendis Pharma As |
Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
|
|
WO2011075471A2
(en)
|
2009-12-18 |
2011-06-23 |
Alcon Research, Ltd. |
Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
|
|
EP2519228A4
(en)
|
2009-12-31 |
2013-06-19 |
Enzon Pharmaceuticals Inc |
POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
|
|
US9561285B2
(en)
|
2010-01-22 |
2017-02-07 |
Ascendis Pharma As |
Carrier-linked carbamate prodrug linkers
|
|
WO2011089215A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
|
US9062094B2
(en)
|
2010-01-22 |
2015-06-23 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
ES2584381T3
(es)
|
2010-05-05 |
2016-09-27 |
Prolynx Llc |
Liberación controlada de compuestos activos desde conjugados macromoleculares
|
|
EP2566334B1
(en)
|
2010-05-05 |
2018-04-18 |
Prolynx, LLC |
Controlled drug release from solid supports
|
|
US9221882B2
(en)
|
2010-05-21 |
2015-12-29 |
Technische Universitat Munchen |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
|
AU2012296951B2
(en)
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
|
CA2843875C
(en)
|
2011-08-12 |
2020-01-07 |
Ascendis Pharma A/S |
High-loading water-soluble carrier-linked prodrugs
|
|
CA2843506C
(en)
|
2011-08-12 |
2020-05-12 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
|
MX349950B
(es)
|
2011-08-12 |
2017-08-22 |
Ascendis Pharma As |
Profarmacos de treprostinil enlazados a un portador.
|
|
EP2741778A1
(en)
|
2011-08-12 |
2014-06-18 |
Ascendis Pharma A/S |
Polymeric hyperbranched carrier-linked prodrugs
|
|
WO2013036857A1
(en)
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
EP2853273A4
(en)
*
|
2012-04-25 |
2016-01-13 |
Daiichi Sankyo Co Ltd |
PROMOTER FOR BONE REPAIR
|
|
CA2868925C
(en)
|
2012-04-25 |
2020-01-21 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
|
|
KR20160118264A
(ko)
|
2014-02-27 |
2016-10-11 |
다이이찌 산쿄 가부시키가이샤 |
스테로이드제 투여로 유발되는 성장 장해에 대한 의약
|
|
CN106456695B
(zh)
|
2014-04-28 |
2019-11-12 |
卫材R&D管理有限公司 |
Hgf的冻干配制品
|
|
US11633487B2
(en)
|
2014-08-06 |
2023-04-25 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
|
EP3242689A1
(en)
|
2015-01-09 |
2017-11-15 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs
|
|
DK3328416T5
(da)
|
2015-07-30 |
2024-10-07 |
Biomarin Pharm Inc |
Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
|
|
HUE057083T2
(hu)
|
2015-12-08 |
2022-04-28 |
Biomarin Pharm Inc |
C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
|
|
ES3064816T3
(en)
|
2016-01-08 |
2026-04-29 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with reduced side-effects
|
|
WO2017118700A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with increased nep stability
|
|
EP3400021A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low npr-c binding
|
|
CA3007976C
(en)
|
2016-01-08 |
2023-09-26 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
DK3400019T3
(da)
|
2016-01-08 |
2022-10-24 |
Ascendis Pharma Growth Disorders As |
CNP-prodrugs med bærerbinding ved ringenheden
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
US11564974B2
(en)
|
2016-09-29 |
2023-01-31 |
Ascendis Pharma Growth Disorders A/S |
Combination therapy with controlled-release CNP agonists
|
|
MX2021001762A
(es)
|
2018-08-16 |
2021-04-19 |
Beyondspring Pharmaceuticals Inc |
Metodo y composicion para estimular la respuesta inmunitaria.
|
|
MX2021008708A
(es)
|
2019-02-11 |
2021-09-21 |
Ascendis Pharma Growth Disorders As |
Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
|